{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    6,
    7,
    8,
    9,
    11,
    12,
    13,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    26,
    27,
    28,
    29
  ],
  "modelUsed": "gemini-3-flash-preview",
  "studyDesignStructure": {
    "studyArms": [
      {
        "id": "arm_1",
        "name": "Group 1: upadacitinib 15 mg QD",
        "type": {
          "code": "Experimental Arm",
          "codeSystem": "USDM",
          "decode": "Experimental Arm"
        },
        "instanceType": "StudyArm",
        "description": "Subjects receive upadacitinib 15 mg once daily for the duration of the study."
      },
      {
        "id": "arm_2",
        "name": "Group 2: upadacitinib 30 mg QD",
        "type": {
          "code": "Experimental Arm",
          "codeSystem": "USDM",
          "decode": "Experimental Arm"
        },
        "instanceType": "StudyArm",
        "description": "Subjects receive upadacitinib 30 mg once daily. Note: Per Amendment 8, subjects on 30mg will be switched to 15mg at their next visit."
      },
      {
        "id": "arm_3",
        "name": "Group 3: Placebo followed by upadacitinib 15 mg QD",
        "type": {
          "code": "Experimental Arm",
          "codeSystem": "USDM",
          "decode": "Experimental Arm"
        },
        "instanceType": "StudyArm",
        "description": "Subjects receive placebo for the first 24 weeks, then switch to upadacitinib 15 mg once daily."
      },
      {
        "id": "arm_4",
        "name": "Group 4: Placebo followed by upadacitinib 30 mg QD",
        "type": {
          "code": "Experimental Arm",
          "codeSystem": "USDM",
          "decode": "Experimental Arm"
        },
        "instanceType": "StudyArm",
        "description": "Subjects receive placebo for the first 24 weeks, then switch to upadacitinib 30 mg once daily."
      }
    ],
    "studyCells": [
      {
        "id": "cell_1",
        "armId": "arm_1",
        "epochId": "epoch_1",
        "elementIds": [
          "elem_1"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_2",
        "armId": "arm_1",
        "epochId": "epoch_2",
        "elementIds": [
          "elem_2"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_3",
        "armId": "arm_1",
        "epochId": "epoch_3",
        "elementIds": [
          "elem_3"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_4",
        "armId": "arm_1",
        "epochId": "epoch_4",
        "elementIds": [
          "elem_4"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_5",
        "armId": "arm_1",
        "epochId": "epoch_5",
        "elementIds": [
          "elem_5"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_6",
        "armId": "arm_2",
        "epochId": "epoch_1",
        "elementIds": [
          "elem_6"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_7",
        "armId": "arm_2",
        "epochId": "epoch_2",
        "elementIds": [
          "elem_7"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_8",
        "armId": "arm_2",
        "epochId": "epoch_3",
        "elementIds": [
          "elem_8"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_9",
        "armId": "arm_2",
        "epochId": "epoch_4",
        "elementIds": [
          "elem_9"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_10",
        "armId": "arm_2",
        "epochId": "epoch_5",
        "elementIds": [
          "elem_10"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_11",
        "armId": "arm_3",
        "epochId": "epoch_1",
        "elementIds": [
          "elem_11"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_12",
        "armId": "arm_3",
        "epochId": "epoch_2",
        "elementIds": [
          "elem_12"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_13",
        "armId": "arm_3",
        "epochId": "epoch_3",
        "elementIds": [
          "elem_13"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_14",
        "armId": "arm_3",
        "epochId": "epoch_4",
        "elementIds": [
          "elem_14"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_15",
        "armId": "arm_3",
        "epochId": "epoch_5",
        "elementIds": [
          "elem_15"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_16",
        "armId": "arm_4",
        "epochId": "epoch_1",
        "elementIds": [
          "elem_16"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_17",
        "armId": "arm_4",
        "epochId": "epoch_2",
        "elementIds": [
          "elem_17"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_18",
        "armId": "arm_4",
        "epochId": "epoch_3",
        "elementIds": [
          "elem_18"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_19",
        "armId": "arm_4",
        "epochId": "epoch_4",
        "elementIds": [
          "elem_19"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_20",
        "armId": "arm_4",
        "epochId": "epoch_5",
        "elementIds": [
          "elem_20"
        ],
        "instanceType": "StudyCell"
      }
    ],
    "studyCohorts": [
      {
        "id": "cohort_1",
        "name": "Bio-IR",
        "instanceType": "StudyCohort",
        "characteristic": "Subjects with moderately to severely active Psoriatic Arthritis who have an inadequate response to at least one biologic DMARD"
      }
    ],
    "studyElements": [
      {
        "id": "elem_1",
        "name": "Group 1: upadacitinib 15 mg QD - Screening",
        "instanceType": "StudyElement",
        "description": "Treatment period for Group 1: upadacitinib 15 mg QD during Screening"
      },
      {
        "id": "elem_2",
        "name": "Group 1: upadacitinib 15 mg QD - Period 1 (Weeks 0-24)",
        "instanceType": "StudyElement",
        "description": "Treatment period for Group 1: upadacitinib 15 mg QD during Period 1 (Weeks 0-24)"
      },
      {
        "id": "elem_3",
        "name": "Group 1: upadacitinib 15 mg QD - Period 1 (Weeks 24-56)",
        "instanceType": "StudyElement",
        "description": "Treatment period for Group 1: upadacitinib 15 mg QD during Period 1 (Weeks 24-56)"
      },
      {
        "id": "elem_4",
        "name": "Group 1: upadacitinib 15 mg QD - Period 2",
        "instanceType": "StudyElement",
        "description": "Treatment period for Group 1: upadacitinib 15 mg QD during Period 2"
      },
      {
        "id": "elem_5",
        "name": "Group 1: upadacitinib 15 mg QD - Follow-up",
        "instanceType": "StudyElement",
        "description": "Treatment period for Group 1: upadacitinib 15 mg QD during Follow-up"
      },
      {
        "id": "elem_6",
        "name": "Group 2: upadacitinib 30 mg QD - Screening",
        "instanceType": "StudyElement",
        "description": "Treatment period for Group 2: upadacitinib 30 mg QD during Screening"
      },
      {
        "id": "elem_7",
        "name": "Group 2: upadacitinib 30 mg QD - Period 1 (Weeks 0-24)",
        "instanceType": "StudyElement",
        "description": "Treatment period for Group 2: upadacitinib 30 mg QD during Period 1 (Weeks 0-24)"
      },
      {
        "id": "elem_8",
        "name": "Group 2: upadacitinib 30 mg QD - Period 1 (Weeks 24-56)",
        "instanceType": "StudyElement",
        "description": "Treatment period for Group 2: upadacitinib 30 mg QD during Period 1 (Weeks 24-56)"
      },
      {
        "id": "elem_9",
        "name": "Group 2: upadacitinib 30 mg QD - Period 2",
        "instanceType": "StudyElement",
        "description": "Treatment period for Group 2: upadacitinib 30 mg QD during Period 2"
      },
      {
        "id": "elem_10",
        "name": "Group 2: upadacitinib 30 mg QD - Follow-up",
        "instanceType": "StudyElement",
        "description": "Treatment period for Group 2: upadacitinib 30 mg QD during Follow-up"
      },
      {
        "id": "elem_11",
        "name": "Group 3: Placebo followed by upadacitinib 15 mg QD - Screening",
        "instanceType": "StudyElement",
        "description": "Treatment period for Group 3: Placebo followed by upadacitinib 15 mg QD during Screening"
      },
      {
        "id": "elem_12",
        "name": "Group 3: Placebo followed by upadacitinib 15 mg QD - Period 1 (Weeks 0-24)",
        "instanceType": "StudyElement",
        "description": "Treatment period for Group 3: Placebo followed by upadacitinib 15 mg QD during Period 1 (Weeks 0-24)"
      },
      {
        "id": "elem_13",
        "name": "Group 3: Placebo followed by upadacitinib 15 mg QD - Period 1 (Weeks 24-56)",
        "instanceType": "StudyElement",
        "description": "Treatment period for Group 3: Placebo followed by upadacitinib 15 mg QD during Period 1 (Weeks 24-56)"
      },
      {
        "id": "elem_14",
        "name": "Group 3: Placebo followed by upadacitinib 15 mg QD - Period 2",
        "instanceType": "StudyElement",
        "description": "Treatment period for Group 3: Placebo followed by upadacitinib 15 mg QD during Period 2"
      },
      {
        "id": "elem_15",
        "name": "Group 3: Placebo followed by upadacitinib 15 mg QD - Follow-up",
        "instanceType": "StudyElement",
        "description": "Treatment period for Group 3: Placebo followed by upadacitinib 15 mg QD during Follow-up"
      },
      {
        "id": "elem_16",
        "name": "Group 4: Placebo followed by upadacitinib 30 mg QD - Screening",
        "instanceType": "StudyElement",
        "description": "Treatment period for Group 4: Placebo followed by upadacitinib 30 mg QD during Screening"
      },
      {
        "id": "elem_17",
        "name": "Group 4: Placebo followed by upadacitinib 30 mg QD - Period 1 (Weeks 0-24)",
        "instanceType": "StudyElement",
        "description": "Treatment period for Group 4: Placebo followed by upadacitinib 30 mg QD during Period 1 (Weeks 0-24)"
      },
      {
        "id": "elem_18",
        "name": "Group 4: Placebo followed by upadacitinib 30 mg QD - Period 1 (Weeks 24-56)",
        "instanceType": "StudyElement",
        "description": "Treatment period for Group 4: Placebo followed by upadacitinib 30 mg QD during Period 1 (Weeks 24-56)"
      },
      {
        "id": "elem_19",
        "name": "Group 4: Placebo followed by upadacitinib 30 mg QD - Period 2",
        "instanceType": "StudyElement",
        "description": "Treatment period for Group 4: Placebo followed by upadacitinib 30 mg QD during Period 2"
      },
      {
        "id": "elem_20",
        "name": "Group 4: Placebo followed by upadacitinib 30 mg QD - Follow-up",
        "instanceType": "StudyElement",
        "description": "Treatment period for Group 4: Placebo followed by upadacitinib 30 mg QD during Follow-up"
      }
    ],
    "summary": {
      "armCount": 4,
      "cellCount": 20,
      "cohortCount": 1,
      "elementCount": 20
    },
    "studyDesign": {
      "id": "sd_1",
      "name": "Study Design",
      "instanceType": "InterventionalStudyDesign",
      "trialIntentTypes": [
        {
          "code": "Treatment",
          "codeSystem": "USDM",
          "decode": "Treatment"
        }
      ],
      "trialType": {
        "code": "Interventional",
        "codeSystem": "USDM",
        "decode": "Interventional"
      },
      "blindingSchema": {
        "code": "Double Blind",
        "codeSystem": "USDM",
        "decode": "Double Blind"
      },
      "maskedRoles": [
        "Subject",
        "Investigator"
      ],
      "randomizationType": {
        "code": "Randomized",
        "codeSystem": "USDM",
        "decode": "Randomized"
      },
      "allocationRatio": {
        "ratio": "2:2:1:1"
      },
      "stratificationFactors": [
        "Extent of psoriasis (>= 3% BSA or < 3% BSA)",
        "Current use of at least 1 DMARD",
        "Number of prior failed biologic DMARDs (1 vs > 1)"
      ],
      "controlType": {
        "code": "Placebo Control",
        "codeSystem": "USDM",
        "decode": "Placebo Control"
      },
      "armIds": [
        "arm_1",
        "arm_2",
        "arm_3",
        "arm_4"
      ],
      "cohortIds": [
        "cohort_1"
      ],
      "therapeuticAreas": [
        "Rheumatology"
      ]
    }
  },
  "rawResponse": [
    {
      "studyDesign": {
        "type": "Interventional",
        "trialIntentTypes": [
          "Treatment"
        ],
        "blinding": {
          "schema": "Double Blind",
          "maskedRoles": [
            "Subject",
            "Investigator"
          ]
        },
        "randomization": {
          "type": "Randomized",
          "allocationRatio": "2:2:1:1",
          "stratificationFactors": [
            "Extent of psoriasis (>= 3% BSA or < 3% BSA)",
            "Current use of at least 1 DMARD",
            "Number of prior failed biologic DMARDs (1 vs > 1)"
          ]
        },
        "controlType": "Placebo",
        "therapeuticAreas": [
          "Rheumatology"
        ]
      },
      "arms": [
        {
          "name": "Group 1: upadacitinib 15 mg QD",
          "type": "Experimental Arm",
          "description": "Subjects receive upadacitinib 15 mg once daily for the duration of the study.",
          "isTitration": false
        },
        {
          "name": "Group 2: upadacitinib 30 mg QD",
          "type": "Experimental Arm",
          "description": "Subjects receive upadacitinib 30 mg once daily. Note: Per Amendment 8, subjects on 30mg will be switched to 15mg at their next visit.",
          "isTitration": false
        },
        {
          "name": "Group 3: Placebo followed by upadacitinib 15 mg QD",
          "type": "Experimental Arm",
          "description": "Subjects receive placebo for the first 24 weeks, then switch to upadacitinib 15 mg once daily.",
          "isTitration": false
        },
        {
          "name": "Group 4: Placebo followed by upadacitinib 30 mg QD",
          "type": "Experimental Arm",
          "description": "Subjects receive placebo for the first 24 weeks, then switch to upadacitinib 30 mg once daily.",
          "isTitration": false
        }
      ],
      "cohorts": [
        {
          "name": "Bio-IR",
          "characteristic": "Subjects with moderately to severely active Psoriatic Arthritis who have an inadequate response to at least one biologic DMARD"
        }
      ],
      "epochs": [
        {
          "name": "Screening",
          "description": "Up to 35 days"
        },
        {
          "name": "Period 1 (Weeks 0-24)",
          "description": "Double-blind, placebo-controlled parallel-group treatment"
        },
        {
          "name": "Period 1 (Weeks 24-56)",
          "description": "Blinded treatment where placebo subjects switch to active upadacitinib"
        },
        {
          "name": "Period 2",
          "description": "Long-term extension (up to 3 years total) initially blinded then open-label"
        },
        {
          "name": "Follow-up",
          "description": "30-day follow-up call or visit"
        }
      ]
    }
  ]
}